Poor
Needs Revision
Patient Risk:
Low
Summary
Only the listed tablet strengths are directly supported by the supplied EUTHYROX label. The liquid formulation, generic and brand availability, pricing, utilization, and switching claims are not established by the label, and the response generalizes a product-specific label to levothyroxine products broadly.
Category Scores
Accurate Statements
Levothyroxine is available in multiple strengths, including 25 mcg, 50 mcg, 75 mcg, and 100 mcg.
Section 3 lists EUTHYROX tablets in 25 mcg, 50 mcg, 75 mcg, and 100 mcg strengths.
Unsupported Statements
Levothyroxine is available as tablets and liquid formulations.
The supplied label describes EUTHYROX tablets only and does not establish availability of liquid formulations.
Levothyroxine is available as generic and brand-name products.
The supplied label does not establish the broader generic and brand-name marketplace.
The price of levothyroxine varies by strength, formulation, brand versus generic status, purchase location, and insurance coverage.
The supplied label contains no pricing, purchase-location, or insurance information.
Most patients use generic levothyroxine.
The supplied label contains no patient-utilization or prescribing data.
Generic levothyroxine usually costs less than brand-name Synthroid.
The supplied label contains no comparative pricing information and does not discuss Synthroid pricing.
The price of generic levothyroxine depends on the dose and quantity dispensed.
The supplied label does not address pricing determinants.
Brand-name levothyroxine, including Synthroid, typically costs more than generic levothyroxine.
The supplied label does not establish comparative brand-versus-generic prices.
People often switch to generic levothyroxine for cost reasons when they are stable on treatment.
The supplied label contains no information about switching frequency, treatment stability, or reasons for switching.
Contradictions
Important Omissions
The response should identify that the cited strength information comes from the product-specific EUTHYROX label rather than presenting it as applying universally to all levothyroxine products.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The claims are primarily product-availability and pricing claims and do not provide dosing or treatment instructions. However, the formulation and marketplace claims are not supported by the supplied label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
Most claims are outside the supplied FDA label, and the response generalizes the EUTHYROX tablet label to levothyroxine products broadly.
Suggested Improvement
Limit label-based statements to the EUTHYROX tablet strengths explicitly listed in Section 3, remove or separately source the liquid, generic-versus-brand, pricing, utilization, and switching claims, and clearly identify the product-specific label.